Health-Related Quality of Life in Adults with Irritable Bowel Syndrome with Constipation: Results of a Combined Analysis of Two Phase 3 Studies with LubiprostoneĪbstract #M1706 Poster Monday, from 8am-5pm PDT Poster presentation from 12pm-2pmĭiscontinuation of Lubiprostone Treatment for Irritable Bowel Syndrome with Constipation is Not Associated with Symptom Increase or Recurrence: Results from a randomized withdrawal studyĪbstract #T1029 Poster Tuesday, from 8am-5pm PDT Poster presentation from 12pm-2pm PDTĭevelopment of an Instrument to Assess Treatment Satisfaction in Patients with Chronic ConstipationĪbstract #T1030 Poster Tuesday, from 8am-5pm PDT Poster presentation from 12pm-2pm PDT Lubiprostone is Effective and Well Tolerated Through 48 Weeks of Treatment in Adults with Irritable Bowel Syndrome and ConstipationĪbstract #T1036 Poster Tuesday, from 8am-5pm PDT Poster presentation from 12pm-2pm What Symptoms Drive Global Symptom Improvement with Lubiprostone in Patients with Irritable Bowel Syndrome and Constipation: Data from Two Multicenter, Randomized, Placebo-controlled TrialsĪbstract #S1272 Poster Sunday, from 8am-5pm PDT Poster presentation from 12pm-2pm IBS is approximately two to two-and-a-half times more prevalent in women than men.Ībstract #157 Oral Sunday, at 3:00pm PDT Although people with IBS-C report many of the symptoms associated with constipation, the presence of abdominal discomfort or pain is what differentiates IBS-C from chronic constipation. In IBS-C, symptoms are present for at least 12 weeks (not necessarily consecutive) over a 12-month period. There are three main types of IBS: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and IBS with mixed constipation and diarrhea (IBS-M). IBS is a disorder characterized by symptoms including recurrent abdominal discomfort or pain, bloating, and changes of bowel habits such as constipation and/or diarrhea. by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America.Ībout Irritable Bowel Syndrome with Constipation (IBS-C) IBS-C is a chronic disorder characterized by abdominal discomfort or pain and changes in bowel habits including symptoms of constipation.ĪMITIZA was developed by Sucampo Pharmaceuticals and is co-marketed in the U.S. “AMITIZA makes it possible for appropriate patients to receive a widely available FDA-approved treatment for their IBS-C,” said Charles Baum, M.D., gastroenterologist and executive medical director, Gastroenterology and Internal Medicine, Takeda Pharmaceuticals North America, Inc.Īpproximately 58 million Americans have Irritable Bowel Syndrome (IBS), and IBS-C accounts for approximately one-third of these cases.
AMITIZA FOR IBS CONSTIPATION HOW TO
Additional data presented at this meeting may help physicians better understand how to treat their patients with IBS-C.” “We are pleased with the body of data on AMITIZA presented at DDW this year. who suffer from this condition,” said Ryuji Ueno, M.D., Ph.D., Ph.D., founder, chairman and chief executive officer, Sucampo Pharmaceuticals (NASDAQ: SCMP). AMITIZA could provide overall symptom relief for the millions of appropriate patients in the U.S.
AMITIZA FOR IBS CONSTIPATION ACTIVATOR
“AMITIZA is the first ClC-2 channel activator and the only widely available FDA-approved agent for the treatment of IBS-C in adult women in the United States.
These data were among others presented at DDW 2008 that evaluated the effect of AMITIZA for IBS-C. Food and Drug Administration (FDA) on Apfor the treatment of IBS-C in women 18 years of age and older, and has been approved since 2006 at a 24 mcg dose for the treatment of Chronic Idiopathic Constipation in adults. “These data are important because they show that in studies, AMITIZA has demonstrated the ability to improve the overall symptoms reported by patients with IBS-C.”ĪMITIZA 8 mcg was approved by the U.S.
Chey, M.D., primary investigator of the study, University of Michigan Health System. “IBS-C is a multi-symptom disorder and is one of the most common conditions seen by gastroenterologists,” said William D. These results were presented at Digestive Disease Week (DDW) 2008, the largest annual international meeting of digestive disease specialists. San Diego, CA – – New study results indicated that treatment with AMITIZA ® (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bowel Syndrome with Constipation (IBS-C).
0 kommentar(er)
